Translational research in hormone receptor-negative breast cancer: mechanisms for early metastasis and prognostic surveillance
博士 === 國立陽明大學 === 臨床醫學研究所 === 107 === Background/aims: About one third of breast cancer tumors are categorized as hormone receptor (HR)-negative subtype and do not respond to hormone therapy. The HR-negative breast cancers, including human epidermal growth factor receptor 2 (HER2) positive or triple...
Main Authors: | Yi-Fang Tsai, 蔡宜芳 |
---|---|
Other Authors: | Muh-Hua Yang |
Format: | Others |
Language: | en_US |
Published: |
2019
|
Online Access: | http://ndltd.ncl.edu.tw/handle/36p8yu |
Similar Items
-
Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer
by: Won, Jennifer Renae
Published: (2015) -
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
by: Sparano, Joseph A., et al.
Published: (2018) -
Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
by: Noman Ahmed Jang Khan MD, et al.
Published: (2021-06-01) -
Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients
by: Henry L. Gómez, et al.
Published: (2010-07-01) -
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
by: Raz Mutai, et al.
Published: (2021-12-01)